Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538636 · ClinicalTrials.gov registry record · NA
Prediction Augmented Screening Initiative
A NA study, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 23,520
- Enrollment target
NCT06538636: Recruiting NA study, sponsored by VA Office of Research and Development.
NCT06538636 is a NA study that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 23,520 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1576% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538636, a NA study, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 23,520 participants
- Enrollment target
Study Summary
Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds cancer at an earlier stage when it is curable, yet only 20% of eligible Veterans have been screened. Uptake is even lower among Black Veterans despite higher lung cancer risk. Using prediction models to identify high-benefit people for whom LCS should be encouraged improves efficiency and reduces disparities. Moreover, it is more patient-centered as shared decision-making conversations can be tailored with personalized information. The US Preventive Services Task Force has called for research to demonstrate that prediction-augmented LCS can be feasibly implemented at the point-of-care. The investigators propose for VA to lead this effort with a large-scale pragmatic clinical trial to show that prediction-augmented LCS is both feasible and improves LCS uptake.
Primary Outcome
The probability of completion of an initial LDCT scan among eligible subjects defined as high-benefit during each quarter of the study (quarter assigned by date of the LDCT order as this event is most proximal to the LCS decision; passage of time between order and scan completion could lead to erroneous attribution of primary outcome to the wrong study phase if scan date is used)
Interventions
- OTHER PCP-Facing Tools
- OTHER LCS team population management tools
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23,520 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2029-09-30 |
| Phase | NA |
What NCT06538636 shows while recruiting
NCT06538636 is an interventional study that assigns participants to a tested intervention. Its 23,520 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (1576% higher).
The record links to 0 conditions, and to 2 interventions - of which PCP-Facing Tools is the first listed.
NCT06538636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06538636 about?
NCT06538636 is a clinical study titled "Prediction Augmented Screening Initiative". Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds ca...
What is the current status of trial NCT06538636?
This trial is currently recruiting. It is a NA study. The enrollment target is 23,520 participants. The study started on 2026-06-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT06538636?
The interventions under investigation include: PCP-Facing Tools (OTHER), LCS team population management tools (OTHER).
Who is sponsoring clinical trial NCT06538636?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06538636's enrollment target sits among peer trials
23,520 10th of 2000 higher than 1,991 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06995898 · 24,000 participants · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI